Mobile website
Treatment of Pleural Fluid and Ascites of Advanced Carcinoma Patients by Tumor Antigen Pulsed Dendritic Cells Combinded with IL-2 Activated Lym-phocyte Infused into Thoracic and Abdominal Cavity
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
To observe the curative effect of tumor antigen pulsed dendritic cells (DCs) combined with interleukin 2 (IL-2) activated lymphocytes infused into thoracic cavity and abdominal cavity on the inhibition of pleural fluid and ascites of advanced carcinoma patients, and to investigate the correlated immune mechanism. Methods: The peripheral blood mononuclear cells of patients suffered from advanced carcinoma were separated as a source of monocyte derived dendritic cells (MoDC) and IL-2-activated lymphocytes. MoDC were pulsed with tumor lysates derived from tumor cells of thoracic or abdominal fluid of patients, combined with IL-2-activated lymphocytes and infused into thoracic cavity and abdominal cavity of the patients. The changes of pleural fluid or ascites of patients were examined by X ray or B supersonic wave. The cytokine receptor on lymphocytes was analysis by FACS. Results: After Immunotherapy, the cancer cells in thoracic cavity and abdominal cavity of the patients were inhibited significantly. The expression of IL-2R on lymphocytes in pleural fluid and ascites was up-regulated and IL-10R was down-regulated. The complete remission rate was 46.9%, part remission rate was 51.3%, and effectual rate was 100 0% of patients received Immunotherapy. Curative effect was effective than that of DDP control( P <0.05). Conclusions: The DC pulsed with tumor antigen combined with IL-2-activated lymphocytes infused into thoracic cavity and abdominal cavity can effectively inhibit the growth of tumor cells. The mechanisms involved may be include: the first, DCs pulsed with tumor antigen may be effectively present the antigen to the T cells in pleural fluid and ascites, which can enhance the specific antitumor immunity; the second, IL-2 activated T cells may also be an effective effector to the tumor cells.
Keywords:
Project Supported:
Clc Number:
